123 related articles for article (PubMed ID: 31570454)
1. Age as a Predictor of Treatment Outcome in Metastatic Testicular Germ Cell Tumors.
Terbuch A; Posch F; Bauernhofer T; Pichler M; Peinsith H; Szkandera J; Riedl J; Hutterer GC; Pummer K; Partl R; Kapp KS; Stöger H; Stotz M; Gerger A
Anticancer Res; 2019 Oct; 39(10):5589-5596. PubMed ID: 31570454
[TBL] [Abstract][Full Text] [Related]
2. Construction and Validation of a Nomogram for Predicting Progression- Free Survival in Patients with Early-Stage Testicular Germ Cell Tumor.
Chen JG; Wang JQ; Peng TW; Chen ZS; Zhao SC
Recent Pat Anticancer Drug Discov; 2021; 16(1):44-53. PubMed ID: 33573563
[TBL] [Abstract][Full Text] [Related]
3. Plasma Cytokines Correlated With Disease Characteristics, Progression-Free Survival, and Overall Survival in Testicular Germ-Cell Tumor Patients.
Svetlovska D; Miskovska V; Cholujova D; Gronesova P; Cingelova S; Chovanec M; Sycova-Mila Z; Obertova J; Palacka P; Rajec J; Kalavska K; Usakova V; Luha J; Ondrus D; Spanik S; Mardiak J; Mego M
Clin Genitourin Cancer; 2017 Jun; 15(3):411-416.e2. PubMed ID: 28237180
[TBL] [Abstract][Full Text] [Related]
4. Age ≥40 Years Is Associated with Adverse Outcome in Metastatic Germ Cell Cancer Despite Appropriate Intended Chemotherapy.
Miller RE; Markt SC; O'Donnell E; Bernard B; Albiges LK; Beard C; Sweeney CJ
Eur Urol Focus; 2017 Dec; 3(6):621-628. PubMed ID: 28753801
[TBL] [Abstract][Full Text] [Related]
5. Systemic inflammatory markers have independent prognostic value in patients with metastatic testicular germ cell tumours undergoing first-line chemotherapy.
Fankhauser CD; Sander S; Roth L; Gross O; Eberli D; Sulser T; Seifert B; Beyer J; Hermanns T
Br J Cancer; 2018 Mar; 118(6):825-830. PubMed ID: 29485982
[TBL] [Abstract][Full Text] [Related]
6. Treatment outcome of metastatic testicular cancer at a single institution in Japan, a country with low incidence of germ cell tumor.
Kawai K; Hinotsu S; Oikawa T; Sekido N; Hattori K; Miyanaga N; Hasegawa Y; Kojima H; Shimazui T; Akaza H
Jpn J Clin Oncol; 2006 Nov; 36(11):723-30. PubMed ID: 17082218
[TBL] [Abstract][Full Text] [Related]
7. Risk of metachronous contralateral testicular germ cell tumors: a population-based study of 7,102 Norwegian patients (1953-2007).
Andreassen KE; Grotmol T; Cvancarova MS; Johannesen TB; Fosså SD
Int J Cancer; 2011 Dec; 129(12):2867-74. PubMed ID: 21626506
[TBL] [Abstract][Full Text] [Related]
8. Clinical utility of plasma miR-371a-3p in germ cell tumors.
Mego M; van Agthoven T; Gronesova P; Chovanec M; Miskovska V; Mardiak J; Looijenga LHJ
J Cell Mol Med; 2019 Feb; 23(2):1128-1136. PubMed ID: 30536846
[TBL] [Abstract][Full Text] [Related]
9. Can we predict chemotherapy response in patients with metastatic testicular cancer? Role of thrombocytosis as a novel marker.
Gokce MI; Mermerkaya M; Süer E; Afandiyev F; Baltaci S
Minerva Urol Nefrol; 2017 Aug; 69(4):342-348. PubMed ID: 27733750
[TBL] [Abstract][Full Text] [Related]
10. Impact of primary metastatic bone disease in germ cell tumors: results of an International Global Germ Cell Tumor Collaborative Group G3 Registry Study.
Oing C; Oechsle K; Necchi A; Loriot Y; De Giorgi U; Fléchon A; Daugaard G; Fedyanin M; Faré E; Bokemeyer C
Ann Oncol; 2017 Mar; 28(3):576-582. PubMed ID: 27993806
[TBL] [Abstract][Full Text] [Related]
11. Late relapses (>2 years) in patients with stage I testicular germ cell tumors: predictive factors and survival.
Fedyanin M; Tryakin A; Kanagavel D; Bulanov A; Burova A; Figurin K; Fainshtein I; Sergeev U; Zakharova T; Garin A; Tjulandin S
Urol Oncol; 2013 May; 31(4):499-504. PubMed ID: 21803619
[TBL] [Abstract][Full Text] [Related]
12. Dose-Dependent Effect of Platinum-Based Chemotherapy on the Risk of Metachronous Contralateral Testicular Cancer.
Blok JM; Groot HJ; Huele EH; de Wit R; Horenblas S; Nuver J; Groenewegen G; Bosch JLHR; Witjes JA; Tromp JM; de Brouwer PJM; van den Berg HA; Vanneste BGL; Smilde TJ; Aarts MJB; Gietema JA; Meijer RP; Schaapveld M
J Clin Oncol; 2021 Feb; 39(4):319-327. PubMed ID: 33119475
[TBL] [Abstract][Full Text] [Related]
13. The importance of the dose of etoposide in the initial treatment of metastatic germ cell tumors and advances in management of patients that relapse.
Marwaha S; Venner PM; North SA
Can J Urol; 2007 Oct; 14(5):3692-6. PubMed ID: 17949524
[TBL] [Abstract][Full Text] [Related]
14. Risk factors in germ cell tumour patients with relapse or progressive disease after first-line chemotherapy: evaluation of a prognostic score for survival after high-dose chemotherapy.
Sammler C; Beyer J; Bokemeyer C; Hartmann JT; Rick O
Eur J Cancer; 2008 Jan; 44(2):237-43. PubMed ID: 18055194
[TBL] [Abstract][Full Text] [Related]
15. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
Fizazi K; Pagliaro L; Laplanche A; Fléchon A; Mardiak J; Geoffrois L; Kerbrat P; Chevreau C; Delva R; Rolland F; Theodore C; Roubaud G; Gravis G; Eymard JC; Malhaire JP; Linassier C; Habibian M; Martin AL; Journeau F; Reckova M; Logothetis C; Culine S
Lancet Oncol; 2014 Dec; 15(13):1442-1450. PubMed ID: 25456363
[TBL] [Abstract][Full Text] [Related]
16. Clinical Outcome of Patients with Fibrosis/Necrosis at Post-Chemotherapy Retroperitoneal Lymph Node Dissection for Advanced Germ Cell Tumors.
Mano R; Becerra MF; Carver BS; Bosl GJ; Motzer RJ; Bajorin DF; Feldman DR; Sheinfeld J
J Urol; 2017 Feb; 197(2):391-397. PubMed ID: 27720783
[TBL] [Abstract][Full Text] [Related]
17. Clinical Outcomes of Metastatic Poor Prognosis Germ Cell Tumors: Current Perspective From a Referral Center.
Necchi A; Farè E; Vullo SL; Giannatempo P; Raggi D; Nicolai N; Piva L; Biasoni D; Catanzaro M; Torelli T; Stagni S; Maffezzini M; Verzoni E; Grassi P; Procopio G; Pizzocaro G; Mariani L; Salvioni R
Clin Genitourin Cancer; 2015 Aug; 13(4):385-391.e1. PubMed ID: 25726505
[TBL] [Abstract][Full Text] [Related]
18. Neutrophil-to-lymphocyte ratio as a predictor of preoperative tumor staging in testicular germ cell tumors.
Jankovich M; Jankovichova T; Ondrus D; Breza J
Bratisl Lek Listy; 2017; 118(9):510-512. PubMed ID: 29061055
[TBL] [Abstract][Full Text] [Related]
19. Orchiectomy after chemotherapy in patients with metastatic testicular cancer. Is it indicated?
Simmonds PD; Mead GM; Lee AH; Theaker JM; Dewbury K; Smart CJ
Cancer; 1995 Feb; 75(4):1018-24. PubMed ID: 7842403
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor receptor and epididymis invasion as prognostic biomarkers in clinical stage I testicular germ cell tumours.
Sanmamed MF; Esteban E; Uriol E; Zarate R; Capelan M; Muriel C; Crespo G; Berros JP; Pardo-Coto P; Perez Q; Alvarez-Fernández C; Jiménez Fonseca P; Luque M; Astudillo A
J Transl Med; 2017 Mar; 15(1):62. PubMed ID: 28320414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
